Novo Nordisk's sales growth went from 14 percent to zero – more uncertainty ahead
Following two quarters of very different sales growth, Novo Nordisk Chief Financial Officer Karsten Munk Knudsen warns of ongoing volatility due to the Covid-19 pandemic. More side effects are expected, but the worst may well be over, according to analyst.
BY KEVIN GRØNNEMANN, TRANSLATED BY NIELSINE NIELSEN
The Covid-19 pandemic has sent Novo Nordisk's turnover on an unexpected roller-coaster ride that is far from over, according to Chief Financial Officer Karsten Munk Knudsen.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
